Stockscreener 앱 받기
197.74
2.67%
-5.42
시간 외 거래:
199.57
1.83
+0.93%
Biogen Inc 주식(BIIB)의 최신 뉴스
Biogen stock trades steady as revenue growth and Alzheimer’s portfolio shape outlook - Ad-hoc-news.de
Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
Former Biogen Executive to Lead Research at Formation Bio - Bloomberg.com
Biogen And The Limitation Of The Tau Approach To Alzheimer's Disease - Seeking Alpha
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Total liabilities & shareholders' equities of Biogen Inc. – BCS:BIIB1 - TradingView
Discontinued operations of Biogen Inc. – BCS:BIIB0 - TradingView
BofA Securities Adjusts Biogen Price Target to $215 From $217 - marketscreener.com
Guggenheim Adjusts Price Target on Biogen to $280 From $260, Maintains Buy Rating - marketscreener.com
BofA cuts Biogen stock price target on higher expectations bar - Investing.com
BofA cuts Biogen stock price target on higher expectations bar By Investing.com - Investing.com Canada
Biogen stock steadies as Alzheimer’s launch and pipeline guide long-term growth - Ad-hoc-news.de
Biogen (BIIB) Expands Its Alzheimer’s Pipeline, Is The 9% Undervaluation Still There? - simplywall.st
FDA 'Gets to Pick the Jury': Steve Uden on Biogen's Tau Gamble and a UK Political Reset - finance.biggo.com
U.K. cabinet shuffle, Taiwan biotech and Biogen data — a BioCentury podcast - biocentury.com
Biogen Inc. stock underperforms Monday when compared to competitors - MarketWatch
Biogen Brings On Spur Therapeutics CEO As Legal Chief - Law360
Goldman Sachs Adjusts Price Target on Biogen to $271 From $250, Maintains Buy Rating - marketscreener.com
Biogen stock edges higher as Alzheimer’s and neuromuscular pipeline shapes outlook - ad-hoc-news.de
Biogen stock trades steady as Alzheimer’s revenue and pipeline shape valuation - ad-hoc-news.de
Biogen’s mixed Alzheimer’s data; Two new startups launch; and more - Endpoints News
Biogen Inc. stock underperforms Friday when compared to competitors - MarketWatch
Bronstein, Gewirtz & Grossman, LLC Is Investigating Biogen Inc. (BIIB) And Encourages Stockholders to Connect - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Will AbbVie's Neuroscience Franchise Deliver Another Strong Quarter? - TradingView
Biogen Taps Biopharmaceutical Veteran as Chief Legal Officer - Bloomberg Law News
Biogen moves forward with Alzheimer's drug candidate following phase 2 study - medwatch.com
Tens of Thousands With Ataxias Can Access Virtual Care - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Is Investigating Biogen Inc. (BIIB) And Encourages Shareholders to Connect - The National Law Review
Rx Rundown: Biogen, Neko Health, Roche and more - Medical Marketing and Media
Is Biogen (BIIB) a Buy, Hold, or Sell Right Now - Kavout | AI
Biogen shares slide as diranersen data raise dosing question - The Pharma Letter
Roche/ Biogen kidney drug granted FDA priority review for label expansion - Seeking Alpha
Autoimmune Disease Therapeutics Market Size to Reach USD 137.85 Billion by 2035 as Biologics and Precision Medicine Drive Growth | SNS Insider - GlobeNewswire Inc.
Biogen Shares Decline After Detailed Diranersen Alzheimer's Study Data - Yahoo Finance
Biogen names Michael Parini as chief legal officer - Investing.com
Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Biogen (BIIB) and Cadrenal Therapeutics, Inc. (CVKD) - The Globe and Mail
Biogen names Michael Parini as chief legal officer By Investing.com - Investing.com Canada
Biogen Appoints Michael J. Parini as Chief Legal Officer - Biogen
Biogen's incoming legal chief has 20 years in biotech leadership - Stock Titan
Form S-1 Biogen Inc For: 15 July By Investing.com - Investing.com Nigeria
AAIC26: Biogen stock drops after unveiling tau-targeting ASO data - Clinical Trials Arena
Tau In The Clinic, Again - Seeking Alpha
Biogen (BIIB) Is Down 6.7% After At-Home LEQEMBI Launch And New Alzheimer’s DataHas The Bull Case Changed? - simplywall.st
Anti-Tau Agent Diranersen Slows Cognitive Decline Across Multiple Endpoints in Phase 2 CELIA Trial, Biogen to Advance to Phase 3 - NeurologyLive
Biogen stock holds steady as Alzheimer portfolio and pipeline shape the long-term story - Ad-hoc-news.de
Biogen (BIIB) Following Fresh Alzheimer’s Data Is The Upside Story Still Intact - Yahoo Finance
Biogen Inc. (BIIB) Presents at Alzheimer's Association International Conference (AAIC Meeting) 2026Slideshow - Seeking Alpha
Biogen Inc (BIIB) Shares Fall 8.2% -- What GF Score of 74 Tells Investors - GuruFocus
Biogen Inc.'s Stock Price Plummets to $191.95, Recording a Sharp 8.17% DropThe Latest Market Update - Smartkarma
Biogen (BIIB) Alzheimer’s Association International Conference (AAIC Meeting) 2026 summary - Quartr
Biogen Backs Alzheimer’s Tau Drug for Phase 3 Despite Trial Miss - Yahoo Finance
BIIB Stock On Track For Worst Day In 2 Years After RBC Questions If Alzheimer’s Drug Benefits Will Replicate In Further Study - Stocktwits
An experimental Alzheimer's drug shows some promise as researchers hunt new approaches - Los Angeles Times
Biogen (BIIB) Shares Face Scrutiny After CELIA Study Results - GuruFocus
Biogen (BIIB) Receives Mixed Feedback on CELIA Study Data - GuruFocus
Biogen’s Alzheimer’s Drug Leaves Questions Unanswered, and That’s a Problem - Barron's
Biogen at aaic 2026: tau drug advances despite mixed trial readout - Investing.com
IBM, Goldman Sachs, SK Hynix, Micron, CrowdStrike, Biogen, and More Stocks That Explain Today's Market -- Barrons.com - Moomoo
Biogen's Alzheimer's drug lowers toxic protein, but results were mixed - Reuters
Biogen (BIIB) Reports Mixed Results on Alzheimer's Drug Diraners - GuruFocus
Biogen Stock Falls After Lackluster Trial Data for Alzheimer's Drug Targeting Tau - Briefs Finance
Biogen Wins FDA Approval for Subcutaneous Starter Dose of Leqembi - Yahoo Finance
Biogen Inc at Alzheimer's Association International Conference (AAIC) Transcript - GuruFocus
Why Is Biogen Stock Falling Tuesday? - Benzinga
Eisai, Biogen report real-world Alzheimer’s drug study results - Investing.com
Biogen tumbles 8.7% as breakthrough Alzheimer’s data is clouded by dosing paradox - Investing.com South Africa
LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer’s Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment - Biogen
Biogen drops after data for novel Alzheimer’s drug (BIIB:NASDAQ) - Seeking Alpha
Nearly 87% of Alzheimer's Patients Chose to Stay on LEQEMBI - Stock Titan
Biogen Drops 7.7% After Morgan Stanley Maintains Equal-Weight - AlphaStreet
0.48%
0.05%
자본화:
|
볼륨(24시간):